Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Corvus Pharmaceuticals, Inc. CRVS
$1.98
-$0.05 (-2.71%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
90338233.00000000
-
week52high
2.34
-
week52low
0.61
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.16089900
-
EPS
-0.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | Overweight | 03 дек 2021 г. |
| Jefferies | Buy | 01 дек 2021 г. | |
| Mizuho | Neutral | Neutral | 03 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 16 июл 2021 г. |
| Cantor Fitzgerald | Overweight | 27 мая 2021 г. | |
| Ladenburg Thalmann | Buy | 07 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jones William Benton | A | 133773 | 20000 | 20 дек 2022 г. |
| MILLER RICHARD A MD | A | 1490119 | 10000 | 14 дек 2022 г. |
| LEA LEIV | A | 133238 | 4000 | 14 дек 2022 г. |
| MILLER RICHARD A MD | A | 1480119 | 50000 | 13 дек 2022 г. |
| LEA LEIV | A | 129238 | 30000 | 13 дек 2022 г. |
| MILLER RICHARD A MD | A | 1394405 | 25000 | 28 сент 2022 г. |
| MILLER RICHARD A MD | A | 1369405 | 5000 | 20 сент 2022 г. |
| MILLER RICHARD A MD | A | 1364405 | 2700 | 20 сент 2022 г. |
| MILLER RICHARD A MD | A | 1361705 | 12300 | 20 сент 2022 г. |
| LEA LEIV | A | 160000 | 160000 | 11 авг 2022 г. |
Новостная лента
The 3 Best Biotech Stocks Under $1 to Buy for April
InvestorPlace
04 апр 2023 г. в 20:21
Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided.
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript
Seeking Alpha
28 мар 2023 г. в 22:55
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2022 Earnings Conference Call March 27, 2023 4:30 PM ET Company Participants Zack Kubow - Investor Relations-Real Chemistry Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President & Chief Executive Officer James Rosenbaum - Senior Vice President-Research Conference Call Participants Mara Goldstein - Mizuho Roger Song - Jefferies Operator Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Fourth Quarter and Full Year 2022 Business Update and Financial Results Conference Call.
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
GlobeNewsWire
21 мар 2023 г. в 16:05
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire
14 мар 2023 г. в 16:35
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseases Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseases
Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022
GlobeNewsWire
05 дек 2022 г. в 08:30
Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT Event will focus on CPI-818 (ITK inhibitor) clinical development and will take place at 4:30 pm ET / 1:30 pm PT